Mydecine Innovations Group’s Director, CEO & Co-Founder, Joshua Bartch chats with our Director of Content, Jill Ettinger.
Similar Posts
Interview With Spencer Hawkswell
In this episode of the Psychedelic Spotlight podcast, we speak with Spencer Hawkswell, CEO of TheraPsil.
Find Your Inner Healing with Psychedelic Therapy | ATMA CEO Interview
In today’s episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA.
ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy.
The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy.
This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend.
In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed.
To learn more about ATMA, visit: https://www.atmajourney.com/
To learn more about Catalyst, visit: https://catalystpresents.ca/
#psychedelics #therapy #magicmushrooms
How to Legally Access Psychedelic Therapy in Canada | The Psychedelic Investor
How can someone legally access psychedelic therapy in Canada? This is the question that I ask David Harder, Founder and Co-CEO of ATMA.
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
By now, most people watching this video are probably aware of the potential for psychedelic medicines, when combined with therapy, such as psilocybin and MDMA to treat a variety of mental health conditions. But receiving this treatment is still difficult.
In Canada, in addition to clinical trials, there are a couple of avenues that a patient can go through to receive psychedelic therapy. The first is called the Section 56 exemption, which has allowed dozens of people suffering from anxiety relating to terminal illnesses to undergo psilocybin therapy.
There is also a new avenue called the Health Canada “Special Access Program”, though relatively few people have gone through that route so far.
In the interview, we also discuss David’s company, ATMA. ATMA is a company that trains therapists to conduct psychedelic therapies. They also conduct therapy themselves.
Lastly, we discuss the upcoming Catalyst Psychedelic conference, happening in Kingston, Ontario between May 20-23rd. I will be there, and I hope to see you also!
MindMed Stock Price Targets [How HIGH can $MMED / $MMEDF Go?]🚀
Today we are going to discuss my 5 year price targets for MindMed, MMEDF on the American OTC market, MMED on the Canadian Neo market and MMQ on the European Frankfurt Stock exchange.
Piggy backing off of a decades worth of positive research showing that substances like LSD, Ibogaine, psilocybin and MDMA can treat mental health illnesses better than current methods by an order of magnitude, MindMed is in my opinion by far the most advanced psychedelic medicines company that retail investors can buy on the public markets which is why MindMedicine is one of my top psychedelic stocks in 2021.
In this video, we’re going to look at 4 different 5 year price targets for MindMed, and assign them a level of probability. The four cases will be:
1. The 5 year bear case for MindMed’s stock
2. The Neutral case for MindMed LT
3. The bull case price target for MindMed
4. The Super Bull case
Timestamps:
0:00 – Intro
2:54 – The Bear Case for MindMed
5:37 – The Neutral Case/ MindMed’s Stagnation
7:49 – The Bull Case for MMED/MMEDF Stock
10:18 – The Super Bull Case for MindMed
13:08 – Note of Caution Plus Answer to Meor’s Nasdaq question
Just as a brief note, in this video we are going to be using MMEDF, and all figures will be in American dollars
And because this is all going to be speculation, the entirety of the episode will take place in, The Speculation Zone
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
Famous Biochemist, Shawn Wells, Tells All About Psychedelics
The World’s leading nutritional biochemist and thought leader on human optimization, Shawn Wells, tells all about psychedelics.